There is endless talk about the impending vaccine and its promise to protect the population from Covid-19. In addition to my thought that massive, frequent testing is the most expedient way out of this public health crisis, I strongly believe that waiting for the vaccine is not the best strategy for helping society. Most vaccines take 2-5 years to develop and distribute. The Covid-19 vaccine is being “fast tracked” and scientists all over the world are contributing their efforts. In the event that this vaccine will be available in 12-18 months or even sooner, will that “fast track” compromise safety…
Browsing: Uncategorized
Three Core Benefits are provided to Virus Project members: Confidence. Our members gain confidence and are highly informed. We scan the globe to deliver the vetted information that is most important that we catalogue. When they need speed to knowledge on virus, they will search Altru not Google. Contribution. Our members make possible finding solutions that can change the trajectory of our life. Whether tests, treatments, vaccines, we help the best and brightest entrepreneurs and scientists globally to connect and collaborate. We empower those who are inspired and solving complex problems. Community. We are a community of thoughtful intelligent citizens…
What is the difference between “oncofertility” and “fertility preservation”? We find it important to use the term “oncofertility” because oncologists often don’t see themselves as fertility specialists. When we coined the term, I think it allowed for more of the cancer community to understand that this is a collaborative discipline where oncologists need to be actively involved in, but don’t have to understand, all of the fertility management strategies, and fertility doctors don’t have to understand all of the oncology side. When this field got started, there was no good way for patients to bridge between their cancer- and fertility-care…
Cancer immunotherapy relies on getting T cells—the immune system’s primary killers of infected and diseased cells—to attack and kill tumor cells. But there’s an important stumbling block for immunotherapy: T cells’ ability to kill can fade, a phenomenon often referred to as exhaustion. Research groups from around the globe have now identified several proteins that appear to play a central role in transforming T cells from powerful destroyers to depleted bystanders with limited capacity to harm cancer cells. A series of recent studies—including three published June 17 in Nature and one initially published May 31 in PNAS—largely zeroed in on one protein in particular, a transcription factor…
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, according to preliminary results from a clinical trial. About 2% of patients with non-small cell lung cancer (NSCLC) have fusions between the RET gene and other DNA segments. These gene fusions can lead to the production of abnormal RET proteins that spur the growth of cancer cells. Selpercatinib (LOXO-292) is a targeted therapy that works by inhibiting the activity of abnormal RET proteins. The drug is an oral therapy that patients take as a pill. In the trial, more patients responded to the drug—that is, their tumors shrank—than has been seen with older drugs…
NuView Life Sciences is a biotechnology company based in Park City, Utah that is focused on precision cancer diagnostics and therapeutics improving patient outcomes and reducing healthcare costs. Founded in 2005, their mission is to change the way many types of cancer are diagnosed and treated using precision medicine technology. The company believes that diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers. NuView aims to accomplish this through the development and clinical application of its…
VPAC1 biomarkers are expressed on cell surfaces in high densities at the onset of oncogenesis. When VPAC1 receptors are targeted, cancer can be diagnosed early, but specifically, it allows physicians to distinguish malignant from benign lesions. NuView’s new NV-VPAC1 technology works as a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer, by combining an NV-VPAC1 peptide with a medical imaging isotope, illuminating cancerous VPAC1 biomarkers for detection and removal. NV-VPAC1™ used in conjunction with a PET scan and fluorescent dye can detect and confirm the shed of cancer cells in voided urine,…
A company is changing the imaging industry with new software that far exceeds all current mammography technology. This breakthrough technology reveals the make up of the entire breast, including what dense tissue usually hides, allowing doctors to see a level of detail unparalleled to anything before. This new approach to machine learning allows both the clinician and artificial intelligence engines to see what is really there and differentiate early stage cancer and other structural abnormalities potentially smaller than 1mm. This level of detail has the potential to provide clinicians significant and critical time advantage, thereby enabling better outcomes: fewer false positives…